I tillæg til den nedsatte eksponering for hormonale præventionsmidler resulterede samtidig administration af fosamprenavir med ritonavir og dette orale præventionsmiddel i klinisk signifikante levertransaminase stigninger hos nogle raske personer.
In addition to the decreased hormonal contraceptive exposures, co-administration of fosamprenavir with ritonavir and this oral contraceptive resulted in clinically significant hepatic transaminase elevations in some healthy subjects.